Burning Rock Biotech Limited (BNR) Stock AnalysisBNRBurning Rock Biotech Limited

Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services. It operates in the Healthcare sector (MEDICAL LABORATORIES industry).

Burning Rock Biotech Ltd is not a good buy right now due to its significant financial losses and declining revenue. The current price is $10.04, with a 52-week high of $41.72, indicating a substantial drop in value. The company has a negative net income of RMB 18.41 million for Q2 2026 and a year-to-date change of -48.98%, highlighting ongoing financial struggles.